These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17886234)

  • 61. Survey of stopping power.
    BRANDT W
    Health Phys; 1958 Jun; 1(1):11-20. PubMed ID: 13598283
    [No Abstract]   [Full Text] [Related]  

  • 62. When it comes to stopping tuberculosis, what is actually "missing"?
    Fatah FZ; Furin J; Pai M
    PLOS Glob Public Health; 2022; 2(3):e0000319. PubMed ID: 36962376
    [No Abstract]   [Full Text] [Related]  

  • 63. Rules every PI should follow.
    Science; 2022 Feb; 375(6583):828. PubMed ID: 35201879
    [No Abstract]   [Full Text] [Related]  

  • 64. Chapter 3: Changing the Rules.
    Editorial team for the Special Issue on Oosawa’s Lectures
    Biophys Physicobiol; 2021; 18():S025-S034. PubMed ID: 36159070
    [No Abstract]   [Full Text] [Related]  

  • 65. Information loss and bias in likert survey responses.
    Westland JC
    PLoS One; 2022; 17(7):e0271949. PubMed ID: 35901102
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparing the Ability of Regression Modeling and Bayesian Additive Regression Trees to Predict Costs in a Responsive Survey Design Context.
    Wagner J; West BT; Elliott MR; Coffey S
    J Off Stat; 2020 Dec; 36(4):907-931. PubMed ID: 34092894
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A new stopping rule for surveys.
    Wagner J; Raghunathan TE
    Stat Med; 2010 Apr; 29(9):1014-24. PubMed ID: 20131311
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adjusting nonresponse bias at subdomain levels using multiple response phases.
    Oleson JJ; He CZ
    Biom J; 2008 Feb; 50(1):58-70. PubMed ID: 17849386
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Geographic Information System mapping as a tool to assess nonresponse bias in survey research.
    Hansen RA; Henley AC; Brouwer ES; Oraefo AN; Roth MT
    Res Social Adm Pharm; 2007 Sep; 3(3):249-64. PubMed ID: 17945157
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Validation, updating and impact of clinical prediction rules: a review.
    Toll DB; Janssen KJ; Vergouwe Y; Moons KG
    J Clin Epidemiol; 2008 Nov; 61(11):1085-94. PubMed ID: 19208371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Stopping rules for surveys with multiple waves of nonrespondent follow-up.
    Rao RS; Glickman ME; Glynn RJ
    Stat Med; 2008 May; 27(12):2196-213. PubMed ID: 17886234
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.